NGM Stock Overview
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NGM Biopharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.54 |
| 52 Week High | US$4.69 |
| 52 Week Low | US$0.60 |
| Beta | 1.27 |
| 1 Month Change | 1.32% |
| 3 Month Change | 14.93% |
| 1 Year Change | -59.79% |
| 3 Year Change | -93.94% |
| 5 Year Change | -90.41% |
| Change since IPO | -89.52% |
Recent News & Updates
Recent updates
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You
Dec 19
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
Oct 05Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates
Aug 09Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky
Jun 27NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't
Apr 17We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully
Dec 20NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails
Oct 17NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President
Jun 30NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022
Jun 21Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jun 15Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week
May 09NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad
Apr 26Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Feb 21We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely
Nov 08Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jul 09NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 06We're Not Very Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
Mar 02Update: NGM Biopharmaceuticals (NASDAQ:NGM) Stock Gained 56% In The Last Year
Jan 26
NGM Bio gives update on 2021 plans and data timeline
Jan 12Shareholder Returns
| NGM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.1% | -0.6% | 1.0% |
| 1Y | -59.8% | 10.6% | 21.9% |
Return vs Industry: NGM underperformed the US Pharmaceuticals industry which returned 15.5% over the past year.
Return vs Market: NGM underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| NGM volatility | |
|---|---|
| NGM Average Weekly Movement | 10.3% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NGM's share price has been volatile over the past 3 months.
Volatility Over Time: NGM's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 138 | David Woodhouse | www.ngmbio.com |
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy.
NGM Biopharmaceuticals, Inc. Fundamentals Summary
| NGM fundamental statistics | |
|---|---|
| Market cap | US$128.53m |
| Earnings (TTM) | -US$142.37m |
| Revenue (TTM) | US$4.42m |
29.1x
P/S Ratio-0.9x
P/E RatioIs NGM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGM income statement (TTM) | |
|---|---|
| Revenue | US$4.42m |
| Cost of Revenue | US$114.23m |
| Gross Profit | -US$109.81m |
| Other Expenses | US$32.56m |
| Earnings | -US$142.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.71 |
| Gross Margin | -2,486.12% |
| Net Profit Margin | -3,223.34% |
| Debt/Equity Ratio | 0% |
How did NGM perform over the long term?
See historical performance and comparison